Patents Assigned to bioTheranostics, Inc.
-
Patent number: 11549148Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: GrantFiled: July 21, 2017Date of Patent: January 10, 2023Assignee: BIOTHERANOSTICS, INC.Inventors: Catherine A. Schnabel, Yi Zhang, Mark G. Erlander
-
Patent number: 11530448Abstract: Methods of determining risk of recurrence of a breast cancer of a subject are provided. Also provided are methods of predicting responsiveness to a therapy of a breast cancer of a subject. Additionally, methods of recommending treatment for a subject that has breast cancer are provided. Further provided are methods of treating a subject that has breast cancer. Systems for performing described methods are also provided.Type: GrantFiled: November 11, 2016Date of Patent: December 20, 2022Assignee: BIOTHERANOSTICS, INC.Inventors: Yi Zhang, Catherine A. Schnabel
-
Patent number: 11430544Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: GrantFiled: December 2, 2016Date of Patent: August 30, 2022Assignee: BIOTHERANOSTICS, INC.Inventors: Mark G. Erlander, Xiao-Jun Ma
-
Patent number: 11078538Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: GrantFiled: October 19, 2016Date of Patent: August 3, 2021Assignee: Biotheranostics, Inc.Inventors: Dennis Sgroi, Mark G. Erlander, Yi Zhang, Catherine A. Schnabel
-
Patent number: 11021754Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: GrantFiled: November 8, 2017Date of Patent: June 1, 2021Assignee: Biotheranostics, Inc.Inventors: Mark G. Erlander, Xiao-Jun Ma, Dennis Sgroi
-
Patent number: 10538816Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: GrantFiled: December 2, 2016Date of Patent: January 21, 2020Assignee: Biotheranostics, Inc.Inventors: Mark G. Erlander, Xiao-Jun Ma
-
Patent number: 10329624Abstract: Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.Type: GrantFiled: April 15, 2016Date of Patent: June 25, 2019Assignees: Biotheranostics, Inc., The General Hospital CorporationInventors: Xiao-Jun Ma, Dennis C. Sgroi, Mark G. Erlander
-
Patent number: 10253369Abstract: Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.Type: GrantFiled: May 28, 2015Date of Patent: April 9, 2019Assignee: BIOTHERANOSTICS, INC.Inventors: Catherine Schnabel, Yi Zhang, Mark G. Erlander
-
Patent number: 9856533Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.Type: GrantFiled: February 6, 2004Date of Patent: January 2, 2018Assignees: Biotheranostics, Inc., The General Hospital CorporationInventors: Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi
-
Patent number: 9670553Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: GrantFiled: July 27, 2015Date of Patent: June 6, 2017Assignee: bioTheranostics, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Patent number: 9447470Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: GrantFiled: March 6, 2010Date of Patent: September 20, 2016Assignees: bioTheranostics, Inc., The General Hospital CorporationInventors: Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi
-
Publication number: 20150344967Abstract: Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.Type: ApplicationFiled: May 28, 2015Publication date: December 3, 2015Applicant: BIOTHERANOSTICS, INCInventors: Catherine Schnabel, Yi Zhang, Mark G. Erlander
-
Publication number: 20150329921Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: July 27, 2015Publication date: November 19, 2015Applicant: bioTheranostics, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Publication number: 20140349856Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: March 24, 2014Publication date: November 27, 2014Applicant: BIOTHERANOSTICS, INC.Inventors: Catherine A. Schnabel, Yi Zhang, Mark G. Erlander
-
Publication number: 20130281502Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: ApplicationFiled: June 10, 2013Publication date: October 24, 2013Applicants: GENERAL HOSPITAL CORPORATION, BIOTHERANOSTICS INC.Inventors: Dennis Sgroi, Mark G. Erlander, Yi Zhang, Catherine A. Schnabel
-
Publication number: 20130023441Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: September 25, 2012Publication date: January 24, 2013Applicant: BIOTHERANOSTICS, INC.Inventor: BIOTHERANOSTICS, INC.
-
Publication number: 20120196761Abstract: The disclosure includes the use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the disclosure provides the identities of genes that are expressed in correlation with the presence of breast cancer, the grade of breast cancer, and the type of breast cancer. The disclosed methods assist in the detection and identification of breast cancer in a patient and so helps determine treatment and clinical outcome, and so prognosis, for the patient. The gene expression levels, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used detect the presence of in situ or invasive breast cancer.Type: ApplicationFiled: August 2, 2011Publication date: August 2, 2012Applicants: GENERAL HOSPITAL CORPORATION, BIOTHERANOSTICS, INC.Inventors: XIAO-JUN MA, Mark Erlander, Sgroi Dennis
-
Patent number: 7930105Abstract: Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.Type: GrantFiled: November 28, 2007Date of Patent: April 19, 2011Assignees: bioTheranostics, Inc., The General Hospital CorporationInventors: Xiao-Jun Ma, Dennis C. Sgroi, Mark G. Erlander
-
Publication number: 20100047787Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis.Type: ApplicationFiled: February 23, 2009Publication date: February 25, 2010Applicants: bioTheranostics, Inc., General Hospital CorporationInventors: Xiao-Jun Ma, Chin-Lee Wu, Mark G. Erlander, William Scott McDougal
-
Patent number: 7504214Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.Type: GrantFiled: December 2, 2003Date of Patent: March 17, 2009Assignee: bioTheranostics, Inc.Inventors: Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi